Phase I study of DRGT-45 in prostate cancer pateints
Latest Information Update: 27 Aug 2021
Price :
$35 *
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Druggability Technologies; Tavanta Therapeutics
- 22 Dec 2016 New trial record
- 09 Dec 2016 Results published in the Media Release